Wedbush Securities

Velocity Trade is a brokerage firm that specializes in providing comprehensive trading services to corporate and institutional clients. The company offers a wide range of market services, including foreign exchange hedging, equity trading, settlement, and corporate finance advisory. By focusing on high-touch stock execution, Velocity Trade enables clients to navigate global exchanges with enhanced risk management and cost-saving opportunities compared to traditional trading models. With a commitment to facilitating efficient trading, Velocity Trade aims to support clients in their trading endeavors across various financial markets.

Valkyrie Investments is a specialized alternative asset management firm.

Sarna Technologies, a subsidiary of Sarna Holdings, specializes in developing advanced trading technologies. It offers a sophisticated buying power and risk monitoring engine, designed to provide real-time pre-trade calculations for securities and complex derivatives. This platform, used by broker-dealers, professional traders, clearing firms, and exchanges, takes account details and position data to output crucial calculations for pre-trade monitoring and settlement, enabling users to leverage the latest technological advancements to meet evolving market demands.

Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for severe autoimmune diseases through targeted therapies. The company's lead candidate, DNTH103, is a monoclonal antibody designed to selectively inhibit a specific component of the immune system, offering potential advantages over existing complement therapies. This treatment aims to improve safety and efficacy for patients suffering from serious autoimmune and inflammatory conditions. Dianthus is committed to advancing its pipeline of next-generation complement therapeutics, supported by a team of experienced professionals in the biotech and pharmaceutical sectors. The company envisions that DNTH103 could be administered as a self-injection for certain patients, enhancing convenience and accessibility in treatment.

Shoreline Biosciences, Inc. is a biotechnology company based in La Jolla, California, founded in 2020. The company specializes in developing cell-based immunotherapies aimed at treating seriously ill patients. Shoreline's proprietary technology platform leverages advanced methods in induced pluripotent stem cell (iPSC) differentiation and genetic programming, specifically targeting the IL-15/CISH pathway. This approach enhances the metabolic fitness and persistence of engineered natural killer (NK) cells, improving their anti-cancer activity. Shoreline's focus includes creating clinically effective immunotherapies using iPSC-derived NK cells and macrophages, providing innovative and cost-effective treatment options for oncology and other serious health conditions.

BioTheryX, Inc. is a clinical-stage biopharmaceutical company based in Chappaqua, New York, that specializes in restoring protein homeostasis through innovative small molecule therapies. The company develops Protein Homeostatic Modulators, including a small molecular glue that targets cereblon for protein degradation, with applications in oncology, inflammation, and other diseases. BioTheryX employs its proprietary PRODEGY platform, which utilizes a library of cereblon binders to design targeted protein degraders (TPDs). Among its key products is BTX-A51, an oral multi-kinase inhibitor aimed at treating specific leukemic stem cell targets and preventing the transcription of oncogenic genes. Founded in 2007, BioTheryX aims to address unmet medical needs by leveraging its expertise in targeted protein degradation.

Sarna Technologies, a subsidiary of Sarna Holdings, specializes in developing advanced trading technologies. It offers a sophisticated buying power and risk monitoring engine, designed to provide real-time pre-trade calculations for securities and complex derivatives. This platform, used by broker-dealers, professional traders, clearing firms, and exchanges, takes account details and position data to output crucial calculations for pre-trade monitoring and settlement, enabling users to leverage the latest technological advancements to meet evolving market demands.

ETF Managers Group is a provider of exchange-traded funds (ETFs) focused on developing innovative thematic ETFs to offer investors unique exposure to new markets. With a lineup that includes a diverse collection of global themes, 75% of which are first-to-market products, the company collaborates with market segment experts to turn portfolio management strategies into successful ETFs. ETF Managers Group showcases the potential of thematic products within investors' portfolios, highlighting the power of the ETF wrapper to deliver long-term growth opportunities.

Kluis Commodities, based in Wayzata, Minnesota, is led by Alan Kluis, a veteran commodity advisor and broker with extensive experience dating back to 1976. The company specializes in offering marketing advice, education, and hedging solutions to farmers, ensuring they effectively navigate commodity markets. Kluis Commodities provides a range of tools and technology designed to enhance the marketing of agricultural produce. In addition to his advisory role, Alan Kluis is a prolific writer, contributing a column to Successful Farming magazine, authoring two books on commodities trading, and producing the weekly newsletter, The Al Kluis Report. He is frequently consulted by major publications and serves as a market analyst on the Linder Farm Radio News Network. Alan’s background in Ag Economics, combined with his roots in farming, informs his commitment to supporting farmers in optimizing their market strategies.

Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company based in Calgary, Canada, dedicated to the discovery and development of innovative cancer therapies. The company's lead product, pelareorep, is an immuno-oncology agent derived from reovirus, designed to treat solid tumors and hematological malignancies by enhancing the immune system's ability to combat cancer. Oncolytics Biotech has established collaboration agreements with Merck KGaA and Pfizer Inc. to explore pelareorep in combination with other treatments for specific types of breast cancer. Additionally, the company is advancing its pipeline with projects such as Bracelet-1 for breast cancer and various cohorts for gastrointestinal cancer. Founded in 1998, Oncolytics Biotech aims to develop effective treatments for cancers that have not responded to existing therapies.

Pacific Growth Equities is a research-driven investment bank specializing in technology-based emerging growth companies, offering a full range of investment banking and brokerage services including Public Equity offerings, Private Equity offerings, and Mergers & Acquisitions. With a focus on life sciences, technology, healthcare, and consumer growth companies, they provide high-quality research for institutional investors and superior execution for corporate clients. Their Sales & Trading team, with an average of 15 years of experience, maintains strong relationships with institutional buyers of emerging growth stocks. As an independent and employee-owned firm, clients have direct access to senior professionals, ensuring hands-on management throughout transactions. Pacific Growth Equities prides itself on its entrepreneurial spirit, innovative approach, and commitment to delivering creative solutions tailored to meet the needs of both institutional and investment banking clients.

Valkyrie Investments is a specialized asset management firm focusing on the intersection of traditional finance and cryptocurrency sectors. Led by industry veterans with extensive experience at firms like Guggenheim Partners and UBS, Valkyrie aims to create and manage portfolios that include exposure to digital assets and other frontier investments. The company's platform provides access to alternative assets, professionally managed by seasoned asset managers, aiming to generate enhanced returns for investors while promoting economic prosperity and technological innovation.